Targets › APOC3
4 programs from 4 companies in 12 trials: 8 Phase 3, 4 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.
Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. (UniProt, P02656)
Open in Phaseline: the race on APOC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals | Olezarsen Apolipoprotein C-III mRNA antisense inhibitor | APOC3 | Phase 3 | Severe Hypertriglyceridemia; Familial Chylomicronemia Syndrome | Mar 2027 |
| Arrowhead Pharmaceuticals | Plozasiran APOC3 antisense oligonucleotide | APOC3 | Phase 3 | Severe Hypertriglyceridemia; Hypertriglyceridemia | Jul 2028 |
| Fujian Shengdi Pharmaceutical | HRS-7249 Injection GalNAc-conjugated APOC3-targeted siRNA | APOC3 | Phase 2 | Hyperlipidemia; Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Jan 2027 |
| Eli Lilly | Solbinsiran (LY3561774) Antisense oligonucleotide targeting APOC3 mRNA, reducing apoC-III levels and triglycerides | APOC3 | Phase 2 | Severe Hypertriglyceridemia | Mar 2027 |
Severe Hypertriglyceridemia (5) Familial Chylomicronemia Syndrome (3) Hyperlipidemia (2) Hypertriglyceridemia (1) Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis (1)
other (3), small molecule (1)
Eli Lilly (1) Ionis Pharmaceuticals (1) Arrowhead Pharmaceuticals (1) Fujian Shengdi Pharmaceutical (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.